S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

RPTX Repare Therapeutics Inc

1.27

-0.05 (-3.79%)

Dec 27 2024 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Repare Therapeutics Charts.

Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Repare Therapeutics Charts.

Repare Therapeutics Inc News

Form 8-K - Current report
Thursday 12 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday 12 December 2024 (2 weeks ago) • Business Wire

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
Tuesday 10 December 2024 (3 weeks ago) • Business Wire

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (1 month ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (1 month ago) • Edgar (US Regulatory)

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Tuesday 12 November 2024 (2 months ago) • Business Wire

Form 424B5 - Prospectus [Rule 424(b)(5)]
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Thursday 7 November 2024 (2 months ago) • Business Wire

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Wednesday 23 October 2024 (2 months ago) • Business Wire

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Monday 14 October 2024 (2 months ago) • Business Wire

More Repare Therapeutics Inc News Articles

Decentral Life (PK)

Bioelectronics (PK)

Northwest Biotherapeutics (QB)

Code Green Apparel (PK)

Rennova Health (CE)

Elite Pharmaceuticals (QB)

Kraig Biocraft Laborator... (QB)

Fannie Mae (QB)

Anavex Life Sciences

Lightwave Logic

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions